

16 November 2020

## **ASX ANNOUNCEMENT**

### **NSW Health Further Expands Lymphoedema Prevention Program**

**Brisbane, Australia** – ImpediMed Limited (ASX:IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health, today announced that New South Wales (NSW) Health is further expanding patient access to its lymphoedema prevention program using the SOZO® Digital Health Platform through the purchase of 25 additional SOZO units. NSW Health is now one of the largest providers of the SOZO Digital Health Platform in Australia, with over 45 units purchased to date.

In April of this year, ImpediMed announced the purchase of eight additional SOZO units, with five of these devices deployed in the Western NSW Local Health District (LHD) of NSW Health. Following successful implementation of the program, NSW Health will use the new devices to further expand patient access in both metropolitan and rural areas.

NSW Health operates over 230 public hospitals in its eight local districts that cover the Sydney metropolitan region and surrounding rural areas. With nearly 45,000 new cancer cases every year, NSW is the largest public health system in Australia. As a connected health platform, SOZO allows patient's care providers to access their lymphoedema measurements at every location in the NSW Health network.

"Together with our distribution partner Regional Health Care Group, we are proud to partner with organisations like NSW Health that are committed to providing access to lymphoedema prevention programs to as many patients as possible," commented Richard Carreon, Managing Director and CEO of ImpediMed. "They are one of a growing list of SOZO users that started small, saw success, and proceeded to build larger programs. Program expansion with existing customers is a critical aspect of our growth strategy in the coming quarters."

The Lymphoedema Prevention Program utilises ImpediMed's Test, Trigger, Treat™ protocol for early detection and intervention of cancer-related lymphoedema. Routine lymphoedema testing of cancer survivors uses the company's SOZO device with BIS (L-Dex®) technology. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial, the largest multi-site, randomised controlled trial ever performed to study lymphoedema prevention, showed that this protocol resulted in a 95% reduction in lymphoedema progression at one year.

The aim of the Lymphoedema Prevention Program is to help educate healthcare providers and patients that with the proper protocols in place, lymphoedema can be detected and managed before it becomes a debilitating chronic condition. Learn more at [www.preventlymphedema.com](http://www.preventlymphedema.com).

**Approved for release by the Managing Director and CEO, Mr Richard Carreon.**

## Contact Details

### Investor Relations Contact:

Mike Bassett, ImpediMed

T : +61 407 431 432

E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

### Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: [kwilliamson@we-worldwide.com](mailto:kwilliamson@we-worldwide.com)

### About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health .

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, body composition, and protein calorie malnutrition, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

### About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

### About SOZO Fluid Analysis for Lymphoedema

The SOZO fluid analysis for lymphoedema provides the L-Dex score to measure fluid build-up in a limb at risk for lymphoedema. By identifying the patient's baseline L-Dex score before cancer treatment and then measuring it at regular intervals post-treatment, healthcare professionals can accurately and objectively monitor patient progress and offer appropriate education and intervention to prevent the progression of lymphoedema. 1-year interim results from the PREVENT Trial showed that this early detection combined with at-home intervention using standard compression therapy can reduce the progression of lymphoedema by 95%. Use of L-Dex and BIS for the clinical assessment of lymphoedema is recommended in multiple clinical practice guidelines including the American Physical Therapy Association, National Lymphedema Network, and Lymphatic Education & Research Network Centers of Excellence program.

For more information, visit: <https://www.impedimed.com/healthcare/cancer-related-lymphedema/>

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.